Search 33,000+ CME courses
Back

PRIME Education, Inc. (PRIME®)

  • Carcinoma, Non-Small-Cell Lung

Optimizing Biomarker Testing and First-Line Treatment Selection in Metastatic NSCLC

Selecting the right first-line therapy for metastatic non-small cell lung cancer (NSCLC) begins with comprehensive and accurate biomarker testing, but real-world challenges in test selection, interpretation, and interdisciplinary coordination can impact patient outcomes. Staying aligned with evolving guidelines and integrating insights from pathology and other specialists are critical to delivering personalized care. In this interactive Clinical Case Challenge, you will work through a newly diagnosed case of metastatic NSCLC, choosing appropriate biomarker tests, interpreting detailed pathology reports, and selecting an evidence-based, targeted treatment approach. See how your decisions compare with your peers and strengthen your clinical practice with expert insights and real-time feedback.

Credit & MOC Details

Credit information is provided by the course provider. We recommend confirming credit eligibility with the provider or your licensing board before starting the activity.

Credit types

IPCE CreditsUp to 0.25 creditsAAPA Category 1 Credit™Up to 0.25 creditsAMA PRA Category 1 Credit™Up to 0.25 creditsNursingUp to 0.25 creditsPharmacyUp to 0.25 credits

MOC types

No MOC

FDA REMS

No

Qualifies for MIPS

No

Target Specialties

Pricing

Free

Reported to ACCME by the provider

  • Case study / clinical scenario
  • Credit · Up to 0.25 credits
  • Commercial Support
  • Released
    Apr 28, 2026
  • Last day to claim credit
    Apr 28, 2027 7 months left

Related courses

See all

Other providers’ courses on the same topic

More from PRIME Education, Inc. (PRIME®)

See all

This provider’s courses closest to this one